Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01994213
Other study ID # FMTN- ?- GEPNET
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 2011
Est. completion date May 2016

Study information

Verified date November 2013
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.

The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumor.


Recruitment information / eligibility

Status Terminated
Enrollment 53
Est. completion date May 2016
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Unresectable advanced or metastatic, histologically-confirmed, gastroenteropancreatic neuroendocrine tumor. Tumors must be considered well-differentiated grade G1 or grade G2 in accordance with WHO 2010 classification.

- Must have at least one measurable disease by RECIST1.1 criteria(tumour lesions =10mm in longest diameter, malignant lymph nodes =15mm in short axis, scanning layer = 5 mm).

- First-line therapy or second-line treatment (second-line treatment i.e. chemotherapy or cytokine therapy as first-line treatment failure or resistant patients).

- No previously received targeted therapy of gastroenteropancreatic neuroendocrine tumor (such as everolimus, sunitinib, or other tyrosine kinase or VEGF inhibitor treatment).

- Age between 18 and 75 years.

- ECOG Performance status = 1.

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Patients with small-cell carcinoma, pheochromocytoma, paraganglioma or Merkel cell carcinoma

- Past or suffering from other cancer, but other than cure basal cell carcinoma and cervical carcinoma in situ

- Participated in other clinical trials within four weeks

- Concurrent therapy with somatostatin analogs(such as octreotide, lanreotide,etc.)

- A variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction)

- Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT or MRI examination revealed brain or leptomeningeal disease

- Subjects received surgery, chemotherapy, radiation therapy, cytokines treatment caused the damage has not been restored, the time interval = 4 weeks, and the wound has not completely healed

- Participants have inadequate organ and marrow function as defined below:

- hemoglobin < 90g/L

- platelets < 100×10^9/L

- neutrophils < 1.5×10^9/L

- total bilirubin = 1.25×ULN

- serum transaminase(ALT and AST ) = 1.5×ULN (If liver metastases are present, serum transaminase= 2.5×ULN)

- creatinine clearance rate = 60ml/min

- cholesterol = 1.5×ULN and triglyceride= 2.5 x ULN,

- LVEF: < 50% by Color Doppler Ultrasonography

- Patients with uncontrollable hypertension after using single agent therapy (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg). Patients with more than Class I, myocardial ischemia or myocardial infarction, arrhythmia (including QT interval = 450ms for male and 470ms for female) and class I heart failure.

- Urine protein = + + and confirmed the 24-hour urinary protein>1.0 g

- Long-term untreated wounds or fractures

- Coagulopathy with bleeding tendency (such as active peptic ulcer)

- Previous artery / venous thromboembolic events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism

- Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) = 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (less than 100mg daily) is allowed

- Female: All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 6 months after the last dose of test article. Child bearing potential, a negative urine or serum pregnancy test result before initiating Famitinib. Male: All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 6 months after the last dose of test article.

- Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot maintain in the normal range

- Abuse of psychiatric drugs or dysphrenia

- Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital immunodeficiency, or organ transplantation

- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Famitinib
Famitinib 25 mg p.o. qd

Locations

Country Name City State
China Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd. Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate 12 weeks
Secondary Progress free survival (PFS) 3 years
Secondary Disease Control Rate (DCR) 3 years
Secondary Overall Survival (OS) 3 years
Secondary Quality of Life 28-day cycle visit until disease progress
Secondary Percent of Participants with OS of one year 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06155318 - 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Completed NCT04852679 - Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs Phase 3
Enrolling by invitation NCT05064150 - Neuroendocrine Tumors - Patient Reported Outcomes
Active, not recruiting NCT04727723 - Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Recruiting NCT06256705 - Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort N/A
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Recruiting NCT04609592 - Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Phase 1
Recruiting NCT05701241 - Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Phase 4
Completed NCT02948946 - Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT04986085 - Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruiting NCT05262556 - NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas Phase 1
Completed NCT03017690 - Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)